DOCSLIB.ORG

Review Apricitabine: a Novel Deoxycytidine Analogue Nucleoside Reverse Transcriptase Inhibitor for the Treatment of Nucleoside-Resistant HIV Infection

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Review Apricitabine: a Novel Deoxycytidine Analogue Nucleoside Reverse Transcriptase Inhibitor for the Treatment of Nucleoside-Resistant HIV Infection Cox 26/4/07 15:06 Page 61 Antiviral Chemistry & Chemotherapy 18:61–70 Review Apricitabine: a novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor for the treatment of nucleoside-resistant HIV infection Mark A Wainberg1, Pedro Cahn2, Richard C Bethell3, James Sawyer4* and Susan Cox5 1McGill University AIDS Center, Lady Davis Institute-Jewish General Hospital, Montreal, Canada 2Fundación Huesped, Buenos Aires, Argentina 3Shire Biochem Inc., Laval, Québec, Canada (presently Boehringer-Ingelheim [Canada] Ltd, Laval, Québec, Canada) 4Prism Ideas, Nantwich, Cheshire, UK 5Avexa Ltd, Richmond, Australia *Corresponding author: Tel: +44 (0) 1270 621 724; Fax: +44 (0) 1270 621 725: E-mail: [email protected] Existing nucleoside reverse transcriptase inhibitors co-administration of ATC together with these for HIV disease are limited by problems of resis- agents will not be possible. The drug is renally tance and, in some cases, long-term toxicity. eliminated, giving a low potential for hepatic drug Apricitabine (ATC; formerly BCH10618, SPD754 interactions. In a double-blind, randomized, and AVX754) is a deoxycytidine analogue nucleo- placebo-controlled Phase II monotherapy trial in side reverse transcriptase inhibitor in clinical antiretroviral-naive patients, ATC doses of development. ATC retains substantial in vitro 1,200 and 1,600 mg/day reduced plasma viral load activity against HIV-1 containing many mutations levels by 1.65 and 1.58 log10 HIV RNA copies/ml, associated with nucleoside reverse transcriptase respectively, after 10 days of treatment (P<0.0001 inhibitor resistance, showing a less than twofold versus placebo). ATC showed a low propensity to reduction in susceptibility in the presence of either select for resistance mutants in vitro and during up to five thymidine analogue mutations or the clinical monotherapy. ATC was well tolerated in M184V mutation. ATC showed a low potential for volunteers and in HIV-infected patients. This cellular or mitochondrial toxicity in vitro. ATC is promising profile suggests that ATC may be useful well absorbed orally, with a bioavailability of in treating patients who have failed previous 65–80%. Its plasma elimination half-life (approxi- lamivudine- or emtricitabine-containing regimens. mately 3 h), and the intracellular half-life of its Further studies to evaluate the long-term efficacy triphosphate (TP) metabolite (6–7 h) support and tolerability of ATC are underway. twice-daily dosing. Intracellular ATC-TP levels are markedly reduced in the presence of lamivu- Keywords: apricitabine, ATC, AVX754, HIV-1, dine or emtricitabine, indicating that clinical reverse transcriptase inhibitors Introduction Nucleoside reverse transcriptase inhibitors (NRTIs) remain resistance, including cross-resistance (Tamalet et al., 2003), central components of almost all the drug combinations used reduce the options for salvage therapy in patients who have in highly active antiretroviral therapy (HAART) for HIV experienced virological failure on their initial regimens disease (Gazzard, et al., 2005; Department of Health and (Deeks, 2004; Gallant, 2005; Wainberg et al., 2005b). Human Services Panel on Antiretroviral Guidelines for Thus, a need for new agents remains, especially for Adults and Adolescents, 2006; Hammer et al., 2006). HAART-experienced patients (Wainberg et al., 2005a). However, existing NRTIs confront two important problems. Apricitabine (ATC; formerly BCH10618, SPD754 First, several of the early NRTIs to be introduced are associ- and AVX754; Avexa, Richmond, Australia) is a single ated with poor long-term tolerability, including effects due to (–)-enantiomer deoxycytidine analogue NRTI in clinical mitochondrial toxicity (Kakuda, 2000; Anderson et al., 2004), development for patients with HIV disease. In common so the commonly used HAART regimens depend heavily with other NRTIs (Ray, 2005), ATC undergoes intracellular on a few, well-tolerated NRTIs. Second, rising levels of activation to the NRTI triphosphate (TP) form before ©2007 International Medical Press 0956-3202 61 Cox 26/4/07 15:06 Page 62 MA Wainberg et al. competing with endogenous deoxynucleotide triphosphates In vitro virological activity for binding to the viral reverse transcriptase (RT) enzyme (De Muys et al., 1999). The subsequent incorporation of the Antiretroviral activity NRTI monophosphate into the nascent viral DNA results ATC-TP has been shown to inhibit wild-type HIV-1 RT in the termination of chain elongation and inhibition of in vitro with an inhibitory constant (Ki) of 0.08 μM, reverse transcription. There are currently only two deoxycy- compared with 0.16 μM for 3TC-TP (De Muys et al., tidine analogue NRTIs approved for the treatment of HIV, 1999). In early studies of its antiretroviral activity, ATC lamivudine (3TC) and emtricitabine (FTC), both of which showed 50% inhibitory concentrations (IC50) against wild- are (–)-enantiomeric compounds. These two agents are type HIV-1 of 1.3 μM (Taylor et al., 2000), 1.45 μM (De cross resistant and cannot be used sequentially following Muys et al., 1999) and 25 μM (Gu et al., 2006). selection of the M184V mutation in RT. ATC might there- The activity of ATC in vitro is maintained in the presence fore represent a new therapeutic option within this subclass of many nucleoside analogue mutations (NAMs) associated for the treatment of experienced patients who have failed with resistance to other NRTIs (De Muys et al., 1999; 3TC or FTC, and also for treatment-naive patients. Taylor et al., 2000; Bethell et al., 2005; Gu et al., 2006). This paper reviews the biochemical, virological and Gu et al. (2006) tested the activity of ATC against 50 clin- pharmacokinetic properties of ATC, together with its clinical ical HIV-1 isolates, of which 45 were NRTI-resistant, efficacy and tolerability in HIV-infected patients. using the Antivirogram™ assay (Monogram Biosciences, Inc., San Francisco, CA, USA). ATC susceptibility was Chemical structure reduced 1.2–2.2-fold against isolates resistant to zidovu- dine (AZT) owing to the presence of the M41L and ATC is the (–)-enantiomer of 2′-deoxy-3′-oxa-4′- T215Y/F thymidine analogue mutations (TAMs), plus a thiocytidine (de Muys et al., 1999; Taylor et al., 2000) median of three additional TAMs, and/or resistant to 3TC (Figure 1). Both the (+)- and (–)-enantiomers of this owing to the M184V mutation. ATC activity was reduced compound have anti-HIV activity in vitro (De Muys et al., 1.3–2.8-fold against isolates resistant to abacavir (ABC; 1999; Taylor et al., 2000; Bethell et al., 2005; Gu et al., that is, L74V, Y115F and M184V plus one other NAM) or 2006) and in HIV-infected patients (Wood et al., 1999; stavudine (d4T; that is, V75T/M, M41L, T215F/Y, and Cahn et al., 2006). However, the racemic mixture exhibited four other NAMs). Insertions at amino acid position 69 significant toxicity in preclinical studies, which was not and viruses containing the Q151M cluster of mutations seen with the single (–)-enantiomer, ATC (Locas C, Ching S (with or without M184V) gave respective reductions in & Damment S [2004] Safety profile of SPD754 in apricitabine activity of 5.2-fold and 14–16-fold, similar or cynomolgus monkeys treated for 52 weeks. 11th Conference lower than the reductions seen with other NRTIs. ATC on Retroviruses and Opportunistic Infections. San Francisco, showed similar activity (IC50: 10–50 µM) against isolates of CA, USA, 8–11 February 2004, Abstract I-17). The (–)- various group M HIV-1 clades, including A/G, B, C, D, enantiomer shows no racemization to the corresponding A(E), D/F, F and H (Gu et al., 2006). As in previous (+)-enantiomer in vivo (Holdich et al., 2006). studies (Taylor et al., 2000), ATC showed additive virolog- ical effects in vitro in combination with other NRTIs (AZT, 3TC, d4T, didanosine [ddI] and ABC), tenofovir (TDF), nevirapine or saquinavir (Gu et al., 2006). Figure 1. Molecular formula structure of apricitabine Subsequently, in response to the observation of a competi- NH2 tive interaction between 3TC and ATC for intracellular phosphorylation (Bethell RC, Adams J, De Muys J, Lippens J, Richard A, Hamelin B, Ren C, Collins P, N Struthers-Semple C, Holdich T & Sawyer J [2004] Pharmacological evaluation of a dual deoxycytidine analogue combination: 3TC and SPD754 [ATC]. 11th O N Conference on Retroviruses and Opportunistic Infections;San Francisco, CA, USA, 8–11 February 2004. Abstract 138), a HO further combination study was undertaken with ATC and S 3TC against a virus bearing the M184V mutation in RT. This modified study design revealed the antagonistic effect of 3TC with regard to the antiviral activity of ATC (Bethell RC, O Collins P,Holdich T & Sawyer J [2004] In vitro and in vivo Molecular weight = 229.26, 1μM = 0.229 μg/ml. antiviral activity of SPD754 [ATC] against wild-type 62 ©2007 International Medical Press Cox 26/4/07 15:06 Page 63 Apricitabine: a new NRTI for HIV-1 disease Figure 2. Fold changes in apricitabine susceptibility in HIV-1 containing according to presence of thymidine analogue mutations in HIV-1 reverse transcriptase A 7.00 3TC 6.00 ABC 5.00 e c ddl 4.00 3.00 TDF resistan d 2.00 ATC Fol 1.00 0.00 Wild-type 41, 215 41, 210, 41, 67, 41, 67, 210, 215 210, 215 215, 219 Location of mutations in reverse transcriptase B 7.00 6.00 5.00 e c 4.00 3.00 resistan d 2.00 Fol 1.00 0.00 Wild-type 67, 70 67, 70, 67, 70, 41, 67, 70, 219 215, 219 215, 219 Location of mutations in reverse transcriptase Apricitabine susceptibility was tested using the PhenoSenseTM HIV assay against wild-type HIV-1 and HIV-1 containing varying patterns of thymidine analogue mutations: accumulated via (A) the 41, 215 pathway (reverse transcriptase codons 41, 67, 210, 215, and 219), and (B) the 67, 70, 219 pathway (codons 41, 67, 70, 215 and 219) (Bethell et al., 2005). ABC, abacavir; ATC, apricitabine; ddl, didanosine; TDF, tenofovir; 3TC, lamivudine.
Load more

Recommended publications
  • Download Article PDF/Slides
    Kan Lu, PharmD New Antiretrovirals for Based on a presentation at prn by Roy M. Gulick, md, mph the Treatment of HIV: Kan Lu, PharmD | Drug Development Fellow University of North Carolina School of Pharmacy Chapel Hill, North Carolina The View in 2006 Roy M. Gulick, md, mph Reprinted from The prn Notebook® | october 2006 | Dr. James F. Braun, Editor-in-Chief Director, Cornell Clinical Trials Unit | Associate Professor of Medicine, Meri D. Pozo, PhD, Managing Editor. Published in New York City by the Physicians’ Research Network, Inc.® Weill Medical College of Cornell University | New York, New York John Graham Brown, Executive Director. For further information and other articles available online, visit http://www.prn.org | All rights reserved. ©october 2006 substantial progress continues to be made in the arena of cokinetics and a long extracellular half-life of approximately 10 hours antiretroviral drug development. prn is again proud to present its annual (Zhu, 2003). During apricitabine’s development, a serious drug interac- review of the experimental agents to watch for in the coming months and tion with lamivudine (Epivir) was noted. Although the plasma years. This year’s review is based on a lecture by Dr. Roy M. Gulick, a long- concentrations of apricitabine were unaffected by coadministration of time friend of prn, and no stranger to the antiretroviral development lamivudine, the intracellular concentrations of apricitabine were reduced pipeline. by approximately sixfold. Additionally, the 50% inhibitory concentration To date, twenty-two antiretrovirals have been approved by the Food (ic50) of apricitabine against hiv with the M184V mutation was increased and Drug Administration (fda) for the treatment of hiv infection.
    [Show full text]
  • Ep 2531027 B1
    (19) TZZ ¥_Z _T (11) EP 2 531 027 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/4985 (2006.01) A61K 31/52 (2006.01) 06.05.2015 Bulletin 2015/19 A61K 31/536 (2006.01) A61K 31/513 (2006.01) A61K 38/55 (2006.01) A61P 31/18 (2006.01) (21) Application number: 11737484.3 (86) International application number: (22) Date of filing: 24.01.2011 PCT/US2011/022219 (87) International publication number: WO 2011/094150 (04.08.2011 Gazette 2011/31) (54) Therapeutic combination comprising dolutegravir, abacavir and lamivudine Therapeutische Zusammensetzung enthaltend Dolutegravir, Abacavir und Lamivudine Combinaison thérapeutique comprenant du dolutégravir, de l’abacavir et de la lamivudine (84) Designated Contracting States: (74) Representative: Gladwin, Amanda Rachel AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GlaxoSmithKline GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Global Patents (CN925.1) PL PT RO RS SE SI SK SM TR 980 Great West Road Designated Extension States: Brentford, Middlesex TW8 9GS (GB) BA ME (56) References cited: (30) Priority: 27.01.2010 US 298589 P WO-A1-2010/011812 WO-A2-2009/148600 US-A1- 2006 084 627 US-A1- 2006 084 627 (43) Date of publication of application: US-A1- 2008 076 738 US-A1- 2009 318 421 12.12.2012 Bulletin 2012/50 US-A1- 2009 318 421 US-B1- 6 544 961 (73) Proprietor: VIIV Healthcare Company • SONG1 et al: "The Effect of Ritonavir-Boosted Research Triangle Park, NC 27709 (US) ProteaseInhibitors on the HIV Integrase Inhibitor, S/GSK1349572,in Healthy Subjects", INTERNET , (72) Inventor: UNDERWOOD, Mark, Richard 15 September 2009 (2009-09-15), XP002697436, Research Triangle Park Retrieved from the Internet: URL:http: North Carolina 27709 (US) //www.natap.org/2009/ICCAC/ICCAC_ 52.htm [retrieved on 2013-05-21] Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Trends in Antiretroviral Treatment in Australia
    AUSTRALIAN HIV OBSERVATIONAL DATABASE (AHOD) ANNUAL REPORT (Volume 20, Number 1: December 2020) 2020 Clinical characteristics of overseas-born men who have sex with men (MSM) in the AHOD cohort and implications for clinical practice In Australia HIV notifications are increasing among overseas-born men who have sex with men (MSM), particularly among Asian-born MSM. Australian evidence suggests that culturally and/or linguistically diverse populations are less likely to start treatment early irrespective of CD4 cell count at diagnosis, but little is known about response once in care. Using data from AHOD, Jolie L Hutchinson and colleagues (2020) compared treatment response in overseas-born MSM from non-English-speaking countries with Australian-born MSM, further categorised based on participation in the Australian Temporary Residents Access Study (ATRAS) which provide temporary residents ineligible for Medicare, access to HIV treatment. ATRAS patients were chosen as the closest surrogate to identifying newly arrived overseas-born MSM. The authors explored the time to first virological suppression (VS) (viral load (VL) <400 copies/mL) and time to virological failure (VF) (>400 copies/mL after suppression). CD4 cell counts and VL measurements were taken at treatment initiation. Adjusted Hazard Ratios (HR) are reported with 95% CI. Results, as shown in figure 1, indicate that overseas-born MSM did not differ significantly in the rate of VS or in the rate of first VF after suppression. This result is different from findings in other settings, and differences may, in part, be explained by the nature of healthcare provision. In Australia, all residents can access ART for free or with a small co-payment; those ineligible for Medicare can get pharmaceutical company-provided ART which is not necessarily straightforward for non-English speakers.
    [Show full text]
  • HIV/AIDS Technologies: a Review of Progress to Date and Current Prospects
    Working Paper No.6 HIV/AIDS Technologies: A review of progress to date and current prospects COMMISSIONED BY: aids2031 Science and Technology Working Group AUTHORED BY: KEITH ALCORN NAM Publications Disclaimer: The views expressed in this paper are those of the author(s) and do not necessarily reflect the official policy, position, or opinions of the wider aids2031 initiative or partner organizations aids2031 Science and Technology working group A review of progress to date and current prospects October 2008 Acronyms 3TC lamivudine ANRS Agènce Nationale de Récherche sur la Sida ART Antiretroviral therapy ARV Antiretroviral AZT azidothymidine or zidovudine bDNA branched DNA CDC US Centers for Disease Control CHER Children with HIV Early Antiretroviral therapy (study) CTL Cytotoxic T-lymphocyte D4T stavudine DSMB Data and Safety Monitoring Board EFV Efavirenz ELISA Enzyme Linked Immunosorbent Assay FDC Fixed-dose combination FTC Emtricitabine HAART Highly Active Antiretroviral Therapy HBAC Home-based AIDS care HCV Hepatitis C virus HPTN HIV Prevention Trials Network HSV-2 Herpes simplex virus type 2 IAVI International AIDS Vaccine Initiative IL-2 Interleukin-2 LED Light-emitting diode LPV/r Lopinavir/ritonavir MIRA Methods for Improving Reproductive Health in Africa trial MSF Médecins sans Frontières MSM Men who have sex with men MVA Modified vaccinia Ankara NIH US National Institutes of Health NRTI Nucleoside reverse transcriptase inhibitor NNRTI Non-nucleoside reverse transcriptase inhibitor OBT Optimised background therapy PCR Polymerase
    [Show full text]
  • Synthesis and Development of Long-Acting Abacavir Prodrug Nanoformulations
    University of Nebraska Medical Center DigitalCommons@UNMC Theses & Dissertations Graduate Studies Summer 8-19-2016 Synthesis and Development of Long-Acting Abacavir Prodrug Nanoformulations Dhirender Singh University of Nebraska Medical Center Follow this and additional works at: https://digitalcommons.unmc.edu/etd Part of the Pharmaceutical Preparations Commons, and the Virus Diseases Commons Recommended Citation Singh, Dhirender, "Synthesis and Development of Long-Acting Abacavir Prodrug Nanoformulations" (2016). Theses & Dissertations. 140. https://digitalcommons.unmc.edu/etd/140 This Dissertation is brought to you for free and open access by the Graduate Studies at DigitalCommons@UNMC. It has been accepted for inclusion in Theses & Dissertations by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. SYNTHESIS AND DEVELOPMENT OF LONG-ACTING ABACAVIR PRODRUG NANOFORMULATIONS by Dhirender Singh A DISSERTATION Presented to the Faculty of the Graduate School in the University of Nebraska Medical Center in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy Department of Pharmaceutical Science Under the Supervision of Dr. Howard E. Gendelman University of Nebraska Medical Center, Omaha, Nebraska August 2016 Supervisory Committee: Howard E. Gendelman, M.D. Ram Mahato, Ph.D JoEllyn M. McMillan, Ph.D. David Oupicky, Ph.D SYNTHESIS AND DEVELOPMENT OF LONG-ACTING ABACAVIR PRODRUG NANOFORMULATIONS Dhirender Singh, Ph.D. University of Nebraska Medical Center, 2016 Supervisor: Howard E Gendelman, M.D. Over the past decade, work from our laboratory has demonstrated the potential of targeted nanoformulated antiretroviral therapy (nanoART) to produce sustained high plasma and tissue drug concentrations for weeks following a single intramuscular (IM) administration that can suppress ongoing viral replication and mitigate dose associated viral resistance.
    [Show full text]
  • 14-258 Phrma HIV/AIDS2014 0819.Indd
    2014 MEDICINES IN DEVELOPMENT REPORT HIV/AIDS PRESENTED BY AMERICA’S BIOPHARMACEUTICAL RESEARCH COMPANIES Biopharmaceutical Company Researchers Are Developing More Than 40 Medicines and Vaccines For HIV Infection Treatment and Prevention Medicines and Vaccines in Globally, approximately 35 million people effective therapies, and preventative Development for HIV Infection are infected with human immunodefi - vaccines. These medicines and vaccines ciency virus (HIV), the virus that causes are either in clinical trials or awaiting Application acquired immune defi ciency syndrome review by the U.S. Food and Drug Submitted (AIDS). However, new infections have Administration (FDA). Phase III dropped by 38 percent since 2001, Phase II The 44 medicines and vaccines in the according to UNAIDS, the Joint United Phase I development pipeline include: Nations Programme on HIV/AIDS. • A fi rst-in-class medicine intended to In the United States, more than 25 prevent HIV from breaking through 1.1 million people are living with HIV the cell membrane. and 15.8 percent of those are unaware they are infected, according to the • A cell therapy that modifi es a U.S. Centers for Disease Control and patient’s own cells in an attempt to Prevention (CDC). Although the U.S. make them resistant to HIV. HIV/AIDS-related death rate has fallen 16 by more than 80 percent since the introduction of antiretroviral therapies in Contents 1995, new HIV infections have stabilized HIV Medicines and Vaccines in at approximately 50,000 each year, Development ......................................2 according to the CDC. Incremental Innovation in HIV/AIDS Treatment .......................... 4 Since AIDS was fi rst reported in 1981, Access to HIV/AIDS Medicines in nearly 40 medicines have been approved Exchange Plans ...................................5 to treat HIV infection in the United Facts About HIV/AIDS ........................7 States.
    [Show full text]
  • Wibke E. Diederich Holger Steuber Editors Therapy of Viral Infections 15 Topics in Medicinal Chemistry
    Topics in Medicinal Chemistry 15 Wibke E. Diederich Holger Steuber Editors Therapy of Viral Infections 15 Topics in Medicinal Chemistry Editorial Board: P. R. Bernstein, Rose Valley, USA A. Buschauer, Regensburg, Germany G. I. Georg, Minneapolis, USA J. A. Lowe, Stonington, USA U. Stilz, Malov, Denmark Prof. Dr. C. T. Supuran, Sesto Fiorentino (Firenze), Italy A. K. Saxena, Lucknow, India Aims and Scope Drug research requires interdisciplinary team-work at the interface between chemistry, biology and medicine. Therefore, the new topic-related series Topics in Medicinal Chemistry will cover all relevant aspects of drug research, e.g. pathobiochemistry of diseases, identification and validation of (emerging) drug targets, structural biology, drugability of targets, drug design approaches, chemogenomics, synthetic chemistry including combinatorial methods, bioorganic chemistry, natural compounds, high-throughput screening, pharmacological in vitro and in vivo investigations, drug-receptor interactions on the molecular level, structure-activity relationships, drug absorption, distribution, metabolism, elimina- tion, toxicology and pharmacogenomics. In general, special volumes are edited by well known guest editors. In references Topics in Medicinal Chemistry is abbreviated Top Med Chem and is cited as a journal. More information about this series at http://www.springer.com/series/7355 Wibke E. Diederich • Holger Steuber Editors Therapy of Viral Infections With contributions by E. Bo¨ttcher-Friebertsha¨user Á U. Chiacchio Á F. Christ Á E. Crespan Á J. Demeulemeester Á Z. Debyser Á U. Dietrich Á W.E. Diederich Á R. Du¨rr Á F.G.R. Ehlert Á C. Frezza Á A. Garbelli Á W. Garten Á S.V. Giofre` Á K. Hardes Á M.
    [Show full text]
  • Background Paper 6.7 Human Immunodeficiency Virus (HIV)/ Acquired Immune Deficiency Syndromes (AIDS)
    Priority Medicines for Europe and the World "A Public Health Approach to Innovation" Update on 2004 Background Paper Written by Warren Kaplan Background Paper 6.7 Human Immunodeficiency Virus (HIV)/ Acquired Immune Deficiency Syndromes (AIDS) By Warren Kaplan, Ph.D., JD, MPH 15 February 2013 Update on 2004 Background Paper, BP 6.7 HIV/AIDS Table of Contents What is new since 2004? ..................................................................................................................................... 4 1. Introduction ................................................................................................................................................. 7 2. What are the Epidemiological Trends for Europe and the World? ................................................... 7 2.1 Western and Central Europe ............................................................................................................. 7 2.2 Eastern Europe .................................................................................................................................... 9 2.2 The World (including Europe) ........................................................................................................ 11 3. What is the Control Strategy? Is There an Effective Package of Control Methods Assembled into a “Control Strategy” for Most Epidemiological Settings?................................................................. 13 3.1 Is there a pharmaceutical ‘gap’? ....................................................................................................
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Patent Application Publication Oo) Pub. No.: US 2015/0284416 Al Zhao (43) Pub
    US 20150284416A1 US 20150284416A1 (19) United States (12) Patent Application Publication oo) Pub. No.: US 2015/0284416 Al Zhao (43) Pub. Date: Oct. 8,2015 (54) NOVEL LINKERS LOR CONJUGATION OL A61K47/48 (2006.01) CELL-BINDING MOLECULES C07K16/32 (2006.01) C07F 9/572 (2006.01) (71) Applicant: Robert Yongxin Zhao, Lexington, MA (US) A61K 31/537 (2006.01) (52) U.S. Cl. (72) Inventor: Robert Yongxin Zhao, Lexington, MA CPC ...........C07F 9/65583 (2013.01); C07F 9/5721 (US) (2013.01); A61K31/537 (2013.01); A61K (73) Assignee: SUZHOU M-CONJ BIOTECH CO., 47/48715 (2013.01); C07K16/32 (2013.01); LTD, Suzhou City (CN) A61K 47/48561 (2013.01 ),A61K 38/05 (2013.01) (21) Appl. No.: 14/740,403 (22) Filed: Jun. 16, 2015 (57) ABSTRACT Publication Classiflcation (51) Int. Cl. Cell binding agent-drug conjugates comprising hydrophilic C07F 9/6558 (2006.01) linkers, and methods of using such linkers and conjugates are A61K38/05 (2006.01) provided. PatentApplication Publication Oct. 8, 2015 Sheet I of 18 US 2015/0284416 Al FIGURES p 0 ° Λ O=PG3 H M /v. A N-VNH2 (Tjn-Vn-II-Ci ho^^nh, (f\-vΝ-Ρ-N ν^'ίOH -78°C, THF 1 H C' Cl --------2—W THO 4 O I Et3N η O O Q NllSZEDtC jf^N -P-NyVjlS0^ N^S I). Drug-SH DMA V HO “ . 2). mAb— (NH2)11 O OPCi3^ I n-vnh2 HO NH2 C' -78°C, THF I). Drug-SH 2). UiAb-(NH2)n 0. KJ kj ■Nj1^—1 Drug-NH2 (T\'VN'v^'"(LNn^-A>SzuV" Dri|8 dr & “V- P Figure I.
    [Show full text]
  • Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase
    Viruses 2010, 2, 606-638; doi:10.3390/v2020606 OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Review Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase Kamalendra Singh, Bruno Marchand, Karen A. Kirby, Eleftherios Michailidis and Stefan G. Sarafianos * Christopher Bond Life Sciences Center & Department of Molecular Microbiology & Immunology, University of Missouri, Columbia, Missouri 65211, USA; E-Mails: [email protected] (K.S.); [email protected] (B.M.); [email protected] (K.A.K.); [email protected] (E.M.) * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-573-882-4338. Received: 2 December 2009; in revised form: 22 January 2010 / Accepted: 3 February 2010 / Published: 11 February 2010 Abstract: HIV-1 Reverse Transcriptase (HIV-1 RT) has been the target of numerous approved anti-AIDS drugs that are key components of Highly Active Anti-Retroviral Therapies (HAART). It remains the target of extensive structural studies that continue unabated for almost twenty years. The crystal structures of wild-type or drug-resistant mutant HIV RTs in the unliganded form or in complex with substrates and/or drugs have offered valuable glimpses into the enzyme’s folding and its interactions with DNA and dNTP substrates, as well as with nucleos(t)ide reverse transcriptase inhibitor (NRTI) and non-nucleoside reverse transcriptase inhibitor (NNRTIs) drugs. These studies have been used to interpret a large body of biochemical results and have paved the way for innovative biochemical experiments designed to elucidate the mechanisms of catalysis and drug inhibition of polymerase and RNase H functions of RT.
    [Show full text]
  • 2013 Prioritisation Report Priority Antiretrovirals for the Medicines
    PRIORITY ANTIRETROVIRALS FOR THE MEDICINES PATENT POOL Third Edition | December 2013 Advancing innovation, access, and public health 1 CONTENTS 3 Introduction 4 Section 1: ARV Prioritisation in Light of New WHO Treatment Guidelines 5 Priority Regimens for Adults 9 Priority Regimens for Children and Adolescents 13 Section 2: Prioritisation of New ARVs and ARVs in the Pipeline 16 Conclusions 18 Annex I - Methodology 22 Annex II - Product Cards 23 Annex IIa: Product Cards for ARVs Prioritised in Light of New WHO Treatment Guidelines 36 Annex IIb: Product Cards for New ARVs and ARVs in the Pipeline 45 Annex IIc: Products in Early Stages of Development* 48 Annex III - Acronyms and Definitions 51 References ACKNOWLEDGMENTS The lead authors of this Working Paper were Esteban Burrone, Head of Policy, and Fernando Pascual, Medical/Pharmaceutical Consultant, of the Medicines Patent Pool. The paper also benefitted from extensive inputs from Robyn Harshaw, Sandeep Juneja, Kaitlin Mara, Chan Park, and Greg Perry. The Medicines Patent Pool (MPP) wants to thank the following external peer reviewers for their comments on an earlier draft: Jintanat Ananworanich, Pascale Boulet, Pedro Cahn, Polly Clayden, Jennifer Cohn, Meg Doherty, Diane Gibb, Raul Gonzalez, Andy Gray, Andrew Hill, Janice Lee, Rohit Malpani, Carmen Pérez-Casas, David Ripin, Marco Vitoria, and the MPP Expert Advisory Group composed of: Labeeb Abboud, Jonathan Berger, Alexandra Calmy, Shing Chang, Carlos Correa, Nelson Juma Otwoma, Eun-Joo Min, Lita Nelsen, Achal Prabhala, Gracia Violeta Ross, Maximiliano Santa Cruz, and Wim Vandevelde. 2 INTRODUCTION TO THE THIRD EDITION OF THE WORKING PAPER Since the first antiretroviral (ARV) information on the patent status, regulatory status received regulatory approval by the US and market trends for different ARVs.
    [Show full text]